China Isotope & RadiationHKSE:01763 -1.78%91 OCF Margin % is 18.09% as of Dec. 2025, which is 24% above its 10-year median of 14.56. GuruFocus rates HKSE:01763 with a GF Score™ of 91/100 and a GF Value™ of HK$15.25 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, China Isotope & Radiation ranks better than 53.01% on this metric.
The historical rank and industry rank for China Isotope & Radiation's OCF Margin % or its related term are showing as below:
HKSE:01763'
s OCF Margin % Range Over the Past 10 Years
Min: 1.28 Med: 14.56 Max: 19.37
Current: 7.56
During the past 11 years, the highest OCF Margin % of China Isotope & Radiation was 19.37%. The lowest was 1.28%. And the median was 14.56%.
HKSE:01763's OCF Margin % is ranked better than 53.01% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 5.86
vs HKSE:01763: 7.56
China Isotope & Radiation OCF Margin % Related Terms
China Isotope & Radiation OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01763 vs ABT, SYK, MDT: OCF Margin % Comparison
For the Medical Devices subindustry, China Isotope & Radiation's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Isotope & Radiation OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's OCF Margin % distribution charts can be found below:
* The bar in red indicates where China Isotope & Radiation's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Isotope & Radiation (HKSE:01763) has a OCF Margin % of 18.09% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on China Isotope & Radiation and its competitors. This is 24% above median its historical median of 14.56. Over the past decade, China Isotope & Radiation's OCF Margin % has ranged from 1.28 to 19.37. According to the industry distribution chart, China Isotope & Radiation ranks #383 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 47%.
Is China Isotope & Radiation's OCF Margin % too high?
China Isotope & Radiation's current OCF Margin % of 18.09% is 24% above median its 10-year median of 14.56. Over the past 10 years, this metric has ranged from a low of 1.28 to a high of 19.37. The Medical Devices & Instruments industry median OCF Margin % is 5.86. China Isotope & Radiation's value of 18.09% is 208.7% above this industry median. Based on the distribution chart, China Isotope & Radiation ranks #383 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, China Isotope & Radiation has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Isotope & Radiation's OCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, China Isotope & Radiation ranks #383 out of 815 companies for OCF Margin %. This puts China Isotope & Radiation in the upper half of its industry. The industry median OCF Margin % is 5.86. China Isotope & Radiation's value of 18.09% is 208.7% above this benchmark. Historically, China Isotope & Radiation's own OCF Margin % has ranged from 1.28 to 19.37 over the past decade. While the company's 10-year median is 14.56 vs. the industry median of 5.86, China Isotope & Radiation has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.86, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Isotope & Radiation's current OCF Margin % of 18.09% is 208.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on China Isotope & Radiation and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Isotope & Radiation's current OCF Margin % is 18.09%, which is 24% above median its own 10-year median of 14.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Isotope & Radiation stock overvalued right now?
Based on GuruFocus' analysis, China Isotope & Radiation (HKSE:01763) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$15.25, compared to a current price of HK$17.67 — trading 15.9% above its estimated fair value. The current OCF Margin % is 18.09%, which is 24% above median its 10-year median of 14.56 and 208.7% above the Medical Devices & Instruments industry median of 5.86. China Isotope & Radiation's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For China Isotope & Radiation (HKSE:01763), the current OCF Margin % is 18.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Isotope & Radiation (HKSE:01763) Overvalued in 2026?
Based on GuruFocus' analysis, China Isotope & Radiation stock appears to be overvalued.
The current stock price of HK$17.67 is trading 15.9% above its estimated GF Value™ of HK$15.25.
GuruFocus considers China Isotope & Radiation to be Modestly Overvalued.
Key valuation signals for HKSE:01763:
OCF Margin %: 18.09% (24% above median its 10-year median of 14.56)
GF Value™: HK$15.25 vs. price of HK$17.67 (15.9% above fair value)
Industry Position: 208.7% above the Medical Devices & Instruments median (#383 of 815)
No single metric tells the full story. See the HKSE:01763 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: (1) nuclear medicine; (2) radioactive source products; (3) irradiation; (4) nuclear medical equipment and related services; and (5) other businesses. Nuclear medicines: manufacturing and sale of a range of imaging diagnostic and therapeutic radio pharmaceuticals imaging, UBT diagnostic kits and test analysers and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The company's operations are carried out and a majority of its customers are located in the PRC.
91GF Score
Get the complete analysis for HKSE:01763
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01763 has been successfully added to your 
